Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: boosting the efficacy of intravenously administered therapeutic adenoviruses

Pau Brugada-Vilà, Anna Cascante, Miguel Ángel Lázaro, Cristina Castells-Sala, Cristina Fornaguera, Maria Rovira-Rigau, Lorenzo Albertazzi, Salvador Borros (Corresponding author), Cristina Fillat (Corresponding author)

Research output: Contribution to journalArticleAcademicpeer-review

30 Downloads (Pure)

Abstract

Oncolytic adenoviruses are used as agents for the treatment of cancer. However, their potential is limited due to the high seroprevalence of anti-adenovirus neutralizing antibodies (nAbs) within the population and the rapid liver sequestration when systemically administered. To overcome these challenges, we explored using nanoparticle formulation to boost the efficacy of systemic oncolytic adenovirus administration. Methods: Adenovirus were conjugated with PEGylated oligopeptide-modified poly(β-amino ester)s (OM-pBAEs). The resulting coated viral formulation was characterized in terms of surface charge, size, aggregation state and morphology and tested for anti-adenovirus nAbs evasion and activity in cancer cells. In vivo pharmacokinetics, biodistribution, tumor targeting, and immunogenicity studies were performed. The antitumor efficacy of the oncolytic adenovirus AdNuPARmE1A coated with OM-pBAEs (SAG101) in the presence of nAbs was evaluated in pancreatic ductal adenocarcinoma (PDAC) mouse models. Toxicity of the coated formulation was analyzed in vivo in immunocompetent mice. Results: OM-pBAEs conjugated to adenovirus and generated discrete nanoparticles with a neutral charge and an optimal size. The polymeric coating with the reporter AdGFPLuc (CPEG) showed enhanced transduction and evasion of antibody neutralization in vitro. Moreover, systemic intravenous administration of the formulation showed improved blood circulation and reduced liver sequestration, substantially avoiding activation of nAb production. OM-pBAEs coating of the oncolytic adenovirus AdNuPARmE1A (SAG101) improved its oncolytic activity in vitro and enhanced antitumor efficacy in PDAC mouse models. The coated formulation protected virions from neutralization by nAbs, as antitumor efficacy was preserved in their presence but was completely lost in mice that received the non-formulated AdNuPARmE1A. Finally, coated-AdNuPARmE1A showed reduced toxicity when high doses of the formulation were administered. Conclusions: The developed technology represents a promising improvement for future clinical cancer therapy using oncolytic adenoviruses.

Original languageEnglish
Pages (from-to)2744-2758
Number of pages15
JournalTheranostics
Volume10
Issue number6
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • Oncolytic adenovirus
  • Pancreatic cancer
  • Poly(β-amino ester)s
  • Polymer-coated viral vectors
  • Systemic delivery

Fingerprint Dive into the research topics of 'Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: boosting the efficacy of intravenously administered therapeutic adenoviruses'. Together they form a unique fingerprint.

  • Cite this

    Brugada-Vilà, P., Cascante, A., Lázaro, M. Á., Castells-Sala, C., Fornaguera, C., Rovira-Rigau, M., Albertazzi, L., Borros, S., & Fillat, C. (2020). Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: boosting the efficacy of intravenously administered therapeutic adenoviruses. Theranostics, 10(6), 2744-2758. https://doi.org/10.7150/thno.40902